Comparison of Rocuronium Induced Neuromuscular Blockade in Late Second Trimester Pregnant and Non-pregnant Women

• Conditions: Pregnancy Related

• Registration Number: NCT04253093
• Lead Sponsor: Hallym University Kangnam Sacred Heart Hospital

Brief Summary

The present study is to compare the onset and duration of rocuronium in late second trimester women and non-pregnant women undergoing general anesthesia.

Detailed Description

Pregnancy induces physiological changes. Plasma volume, cardiac output, hepatic blood flow and protein binding are changed from the first trimester of pregnancy. These physiological changes give effect to the onset and duration of neuromuscular blocking drugs.

Rocuronium is a commonly used neuromuscular blocking drug categorized as FDA category B. Rocuronium is widely used for pregnant women. Previous studies have evaluated the onset and duration of rocuronium in postpartum women. Lately, the investigators have evaluated the onset and duration of rocuronium in early second trimester pregnant women and the duration was significantly longer in early second trimester women compared to non-pregnant women.

Since there is little research on the onset and duration of rocuronium in the late second trimester pregnant women, the investigators planned the present research.

Study Timeline

• Study Start: 2019-08-01
• Status Verified: 2020-01
• Study First Submitted: 2020-01-29
• Study First Submitted QC: 2020-01-31
• Last Update Submitted: 2020-01-31
• Study First Posted: 2020-02-05
• Last Update Posted: 2020-02-05
• Primary Completion: 2020-10-01
• Study Completion: 2020-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 50

Inclusion Criteria

• women undergoing general anesthesia

Exclusion Criteria

• liver disease
• renal disease
• diabetes mellitus
• asthma
• allergic to specific drugs
• BMI>30 or <18

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
duration of rocuronium	time measured to 25% recovery with T1 using Train of Four watch, assessed upto 1 hour	time measured with TOFwatch-SX

Secondary Outcome Measures

Name	Time	Method
onset of rocuronium	time measured to 0% depression of T1 using Train of Four watch, assessed upto 5 minutes	time measured with TOFwatch-SX

Trial Locations

Locations (1)

Kangnam sungshim hospital; 🇰🇷 Seoul, Korea, Republic of